Kyle Gano - 16 Jan 2026 Form 4 Insider Report for NEUROCRINE BIOSCIENCES INC (NBIX)

Role
Chief Executive Officer, Director
Signature
/s/ Darin Lippoldt, Attorney-in-Fact
Issuer symbol
NBIX
Transactions as of
16 Jan 2026
Net transactions value
-$3,520,422
Form type
4
Filing time
20 Jan 2026, 18:56:20 UTC
Previous filing
04 Nov 2025
Next filing
03 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Gano Kyle Chief Executive Officer, Director 6027 EDGEWOOD BEND CT., SAN DIEGO /s/ Darin Lippoldt, Attorney-in-Fact 20 Jan 2026 0001567160

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NBIX Common Stock Options Exercise $1,244,822 +34,588 +25% $35.99 174,995 16 Jan 2026 Direct
transaction NBIX Common Stock Sale $4,589,980 -34,588 -20% $132.70 140,407 16 Jan 2026 Direct F1, F2
transaction NBIX Common Stock Options Exercise $65,214 +1,812 +1.3% $35.99 142,219 16 Jan 2026 Direct
transaction NBIX Common Stock Sale $240,478 -1,812 -1.3% $132.71 140,407 16 Jan 2026 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NBIX Non-Qualified Stock Option Options Exercise $0 -34,588 -100% $0.000000 0 16 Jan 2026 Common Stock 34,588 $35.99 Direct F4
transaction NBIX Incentive Stock Option Options Exercise $0 -1,812 -100% $0.000000 0 16 Jan 2026 Common Stock 1,812 $35.99 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on May 20, 2025. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
F2 Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $131.42 to $133.98. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range
F3 Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $131.49 to $133.79. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range
F4 The option was granted February 5, 2016 and vested in 48 equal monthly installments beginning on March 5, 2016. These options were due to expire on February 5, 2026.